Prøve GULL - Gratis
Two to six, where is the fix?
Chronicle Pharmabiz
|July 24, 2025
THERE is a debate going on in the circle of highly qualified pharmacists, especially among the pharmacy teachers, that, what should be the minimum duration of pharmacist course. This is intensified after the Pharmacy Council of India announced its decision of splitting B. Pharm course into B. Pharm Industrial and B. Pharm Clinical courses. But there are lot of voices for and few against the proposal. Some even suggesting entirely a new course. Let us discuss the pros and cons of all those views in brief.
Two years pharmacist course
The people for it are conservatives or self-centered who do not want to disturb existing [for more than half a Century!] 2 years D. Pharm course. They are obviously not for the upgradation of the profession, as it may affect their business and profit! Resisting all move to upgrade the course with all their might and influence for decades, these people want to maintain status co. Now knowingly or unknowingly National Education Policy [NEP] also promotes their interest and PCI has announced it is for continuation of D. Pharm course and those who leave the B. Pharm course abruptly in the middle [after 2 years of course!] will be given Diploma in Pharmacy as per NEP. Is it not a super idea? Will they give similar diploma for the students who leave after second year MBBS? When there can be semi-baked pharmacists, why not half cooked doctors? They will make an excellent pair married to serve and save humanity! PCI which has announced earlier, its intension to abolish D. Pharm is now back tracking, simply to please their masters in the government by showing they have faithfully implemented NEP. It is more important than upgrading the profession, you know! It may be apt to quote here a para from my earlier article “Boot is on the other leg, come forward PCI” published in Pharmabiz dated 9.12.2020. “If a country is progressing means, it should upgrade its professional services by a diploma to degree to post graduate to doctoral to post-doctoral professional. Instead, we will retain all these level professional means where is the logic? Look at the developed countries, in pharmacy profession, they have moved from one year diploma to 6 years Pharm. D or M. Pharm [and stopping all short-term courses]. That is progress! Just to justify its action of prolonging D. Pharm, PCI is hiding behind NEP, we believe.” Remember it was written almost 5 years back!
Three years course
Denne historien er fra July 24, 2025-utgaven av Chronicle Pharmabiz.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Chronicle Pharmabiz
Chronicle Pharmabiz
Home-grown CAR-T cell therapies gaining ground
INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.
4 mins
November 27, 2025
Chronicle Pharmabiz
NPPA extends price fixation on orthopaedic implants for 1 year
IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.
1 mins
November 27, 2025
Chronicle Pharmabiz
FICCI envisages it's Smart AAMs to boost healthcare
In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.
1 min
November 27, 2025
Chronicle Pharmabiz
DoP asked to bring policy for affordable drug pricing
THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.
1 mins
November 27, 2025
Chronicle Pharmabiz
Ramaiah emphasises need for bone health and osteoporosis diagnosis
RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.
2 mins
November 27, 2025
Chronicle Pharmabiz
Nathealth calls for action in 2026-27 Union Budget
NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.
1 mins
November 27, 2025
Chronicle Pharmabiz
Hotspots & growth opportunities in biomanufacturing
THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.
3 mins
November 27, 2025
Chronicle Pharmabiz
Omega Hospitals acquires Cytecare Hospitals
Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.
2 mins
November 27, 2025
Chronicle Pharmabiz
Devices sector hails withdrawal of QCOs
THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.
1 min
November 27, 2025
Chronicle Pharmabiz
'There is urgent need for tech-focused regulatory approach for med devices'
THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.
2 mins
November 27, 2025
Listen
Translate
Change font size
